Vascular Solutions (Nasdaq: VASC) reported earnings on July 24. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended June 30 (Q2), Vascular Solutions beat expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP earnings per share grew.

Gross margins improved, operating margins increased, net margins dropped.

Revenue details
Vascular Solutions booked revenue of $24.7 million. The five analysts polled by S&P Capital IQ anticipated revenue of $24.2 million on the same basis. GAAP reported sales were 11% higher than the prior-year quarter's $22.3 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.15. The three earnings estimates compiled by S&P Capital IQ forecast $0.13 per share. GAAP EPS of $0.15 for Q2 were 15% higher than the prior-year quarter's $0.13 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 66.7%, 70 basis points better than the prior-year quarter. Operating margin was 15.9%, 70 basis points better than the prior-year quarter. Net margin was 9.6%, 10 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $24.2 million. On the bottom line, the average EPS estimate is $0.14.

Next year's average estimate for revenue is $97.7 million. The average EPS estimate is $0.55.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 95 members out of 107 rating the stock outperform, and 12 members rating it underperform. Among 25 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 20 give Vascular Solutions a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Vascular Solutions is buy, with an average price target of $14.30.

The healthcare investing landscape is littered with also-rans and a few major winners. Is Vascular Solutions the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Get instant access to this free report.